SCINAI IMMUNOTHERAPEUTICS LTD. Finance Costs
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Finance Costs of ILS 3.64 million for the 3-month period ending 2022-06-30, per its 6-K/A filed 2022-08-29.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2022-08-29
- SCINAI IMMUNOTHERAPEUTICS LTD. finance costs for the quarter ending 2022-06-30 was 3.64M ILS, a 17.83% increase year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. finance costs for the quarter ending 2021-12-31 was 2.72M ILS, a 252.26% increase year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. finance costs for the quarter ending 2021-09-30 was 2.80M ILS, a 872.57% increase year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. finance costs for the quarter ending 2021-06-30 was 3.09M ILS, a 78.83% decline year-over-year.
ILS
| Period end | Finance Costs 3 month | Finance Costs 6 month | Finance Costs 9 month | Finance Costs 12 month |
|---|---|---|---|---|
| 2022-06-30 | 3.64M ILS 6-K/A · filed 2022-08-29 | 5.98M ILS 6-K/A · filed 2022-08-29 | ||
| 2021-12-31 | 2.72M ILS derived: 6-K/A 12 month − 6-K/A 9 month · filed 2022-08-29 | 5.52M ILS derived: sum of 2 quarters · filed 2022-08-29 | 8.62M ILS derived: sum of 3 quarters · filed 2022-08-29 | 10.87M ILS 6-K/A · filed 2022-08-29 |
| 2021-09-30 | 2.80M ILS 6-K/A · filed 2021-12-27 | 5.89M ILS derived: sum of 2 quarters · filed 2022-08-29 | 8.14M ILS 6-K/A · filed 2021-12-27 | |
| 2021-06-30 | 3.09M ILS 6-K/A · filed 2022-08-29 | 5.34M ILS 6-K/A · filed 2022-08-29 | ||
| 2020-12-31 | 773.00K ILS derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | 1.06M ILS derived: sum of 2 quarters · filed 2022-03-28 | 15.66M ILS derived: sum of 3 quarters · filed 2022-03-28 | 15.63M ILS 20-F · filed 2022-03-28 |
| 2020-09-30 | 288.00K ILS 6-K/A · filed 2021-12-27 | 14.89M ILS derived: sum of 2 quarters · filed 2021-12-27 | 14.86M ILS 6-K/A · filed 2021-12-27 | |
| 2020-06-30 | 14.60M ILS 6-K · filed 2020-10-02 | 14.75M ILS 6-K · filed 2020-10-02 | ||
| 2019-12-31 | 10.25M ILS derived: 20-F 12 month − 6-K 9 month · filed 2022-03-28 | 10.86M ILS derived: sum of 2 quarters · filed 2022-03-28 | 38.55M ILS derived: sum of 3 quarters · filed 2022-03-28 | 30.85M ILS 20-F · filed 2022-03-28 |
| 2019-09-30 | 601.00K ILS 6-K · filed 2021-01-28 | 28.30M ILS derived: sum of 2 quarters · filed 2021-01-28 | 20.59M ILS 6-K · filed 2021-01-28 | |
| 2019-06-30 | 27.70M ILS 6-K · filed 2020-10-02 | 19.99M ILS 6-K · filed 2020-10-02 | ||
| 2018-12-31 | 13.60M ILS 20-F · filed 2021-05-13 | |||
| 2017-12-31 | 10.91M ILS 20-F · filed 2020-06-12 | |||
| 2016-12-31 | 303.00K ILS 20-F · filed 2019-04-30 | |||
| 2015-12-31 | 24.00K ILS 20-F · filed 2018-04-30 |
USD
| Period end | Finance Costs 3 month | Finance Costs 6 month | Finance Costs 9 month | Finance Costs 12 month |
|---|---|---|---|---|
| 2022-06-30 | $1.71M 6-K/A · filed 2022-08-29 | |||
| 2021-12-31 | $972.00K derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | $3.49M 20-F · filed 2022-03-28 | ||
| 2021-09-30 | $2.52M 6-K/A · filed 2021-12-27 | |||
| 2020-12-31 | $4.86M 20-F · filed 2021-05-13 | |||
| 2017-12-31 | $3.15M 20-F · filed 2018-04-30 |